AIM: The aim of this paper was to investigate the predictive value of ankle-brachial index (ABI) and blood glucose to estimate mortality in Chinese type 2 diabetes patients. METHODS: Chinese type 2 diabetes patients (1706 subjects) were followed up for about 6 years, RESULTS: One thousand four hundred fourteen were included in the final statistical analysis during a median follow-up of 69 months. Overall, 398 patients died during follow-up and 254 deaths were attributable to cardiovascular disease (CVD). Relative risks of all-cause and CVD mortality of patients with ABI≤0.4 were increased by 2.073-fold (95% CI: 1.236-3.478) and 3.086-fold (95% CI: 1.702-5.595), compared with those of patients with ABI>1.0 and ≤1.4. Mortality was significantly increased with increasing plasma glucose and decreasing ABI. All-cause and CVD mortality was the highest (55.6% and 44.4%) with ABI≤0.4 and plasma glucose >10 mmol/L simultaneously. Relative risks of all-cause and CVD mortality in these patients were increased by 3.905-fold (95% CI: 1.334-11.431) and 3.771-fold (95% CI: 1.079-13.171), compared with patients with ABI>1.0 and ≤1.4, and plasma glucose ≤6 mmol/L simultaneously. Models to evaluate additional predictive value of ABI for mortality of type 2 diabetes patients suggested that addition of ABI significantly improved the prediction of the death rate compared with the model including conventional risk factors only. CONCLUSION: High plasma glucose and low ABI had synergistic effects on increasing mortality of type 2 diabetes patients. The addition of ABI can significantly improve the prediction of mortality compared to protocol using conventional risk factors only.
AIM: The aim of this paper was to investigate the predictive value of ankle-brachial index (ABI) and blood glucose to estimate mortality in Chinese type 2 diabetespatients. METHODS: Chinese type 2 diabetespatients (1706 subjects) were followed up for about 6 years, RESULTS: One thousand four hundred fourteen were included in the final statistical analysis during a median follow-up of 69 months. Overall, 398 patients died during follow-up and 254 deaths were attributable to cardiovascular disease (CVD). Relative risks of all-cause and CVD mortality of patients with ABI≤0.4 were increased by 2.073-fold (95% CI: 1.236-3.478) and 3.086-fold (95% CI: 1.702-5.595), compared with those of patients with ABI>1.0 and ≤1.4. Mortality was significantly increased with increasing plasma glucose and decreasing ABI. All-cause and CVD mortality was the highest (55.6% and 44.4%) with ABI≤0.4 and plasma glucose >10 mmol/L simultaneously. Relative risks of all-cause and CVD mortality in these patients were increased by 3.905-fold (95% CI: 1.334-11.431) and 3.771-fold (95% CI: 1.079-13.171), compared with patients with ABI>1.0 and ≤1.4, and plasma glucose ≤6 mmol/L simultaneously. Models to evaluate additional predictive value of ABI for mortality of type 2 diabetespatients suggested that addition of ABI significantly improved the prediction of the death rate compared with the model including conventional risk factors only. CONCLUSION: High plasma glucose and low ABI had synergistic effects on increasing mortality of type 2 diabetespatients. The addition of ABI can significantly improve the prediction of mortality compared to protocol using conventional risk factors only.
Authors: Christopher E Clark; Fiona C Warren; Kate Boddy; Sinead T J McDonagh; Sarah F Moore; John Goddard; Nigel Reed; Malcolm Turner; Maria Teresa Alzamora; Rafel Ramos Blanes; Shao-Yuan Chuang; Michael Criqui; Marie Dahl; Gunnar Engström; Raimund Erbel; Mark Espeland; Luigi Ferrucci; Maëlenn Guerchet; Andrew Hattersley; Carlos Lahoz; Robyn L McClelland; Mary M McDermott; Jackie Price; Henri E Stoffers; Ji-Guang Wang; Jan Westerink; James White; Lyne Cloutier; Rod S Taylor; Angela C Shore; Richard J McManus; Victor Aboyans; John L Campbell Journal: Hypertension Date: 2020-12-21 Impact factor: 10.190
Authors: Lia Alves-Cabratosa; Marc Comas-Cufí; Anna Ponjoan; Maria Garcia-Gil; Ruth Martí-Lluch; Jordi Blanch; Marc Elosua-Bayes; Dídac Parramon; Lourdes Camós; Lidia Guzmán; Rafel Ramos Journal: BMJ Open Diabetes Res Care Date: 2020-03